



RETURN BIDS TO:

RETOURNER LES SOUMISSIONS À:

Drugs, Vaccines and Biologics Division/Div.des
produits pharmaceutiques,biologiques et de vaccins
10 Wellington Street
Gatineau
Québec
K1A 0S5

**LETTER OF INTEREST
LETTRE D'INTÉRÊT**

Comments - Commentaires

Vendor/Firm Name and Address
Raison sociale et adresse du
fournisseur/de l'entrepreneur

Issuing Office - Bureau de distribution

Drugs, Vaccines and Biologics Division/Div.des produits
pharmaceutiques,biologiques et de vaccins
Terrasses de la Chaudière 5th Floo
10 Wellington Street
Gatineau
Quebec
K1A 0S5

Title - Sujet Methotrimprazine	
Solicitation No. - N° de l'invitation E60PH-20MPRA/B	Date 2020-05-21
Client Reference No. - N° de référence du client E60PH-20MPRA	GETS Ref. No. - N° de réf. de SEAG PW-\$\$PH-893-78751
File No. - N° de dossier ph893.E60PH-20MPRA	CCC No./N° CCC - FMS No./N° VME
Solicitation Closes - L'invitation prend fin at - à 02:00 PM on - le 2020-06-04	
Time Zone Fuseau horaire Eastern Daylight Saving Time EDT	
F.O.B. - F.A.B. Specified Herein - Précisé dans les présentes Plant-Usine: ☐ Destination: ☐ Other-Autre: ☒	
Address Enquiries to: - Adresser toutes questions à: Vettoretti(ph893), Eric	Buyer Id - Id de l'acheteur ph893
Telephone No. - N° de téléphone (613) 286-6065 ()	FAX No. - N° de FAX (819) 956-8303
Destination - of Goods, Services, and Construction: Destination - des biens, services et construction: See Herein	

Instructions: See Herein

Instructions: Voir aux présentes

Delivery Required - Livraison exigée	Delivery Offered - Livraison proposée
Vendor/Firm Name and Address Raison sociale et adresse du fournisseur/de l'entrepreneur	
Telephone No. - N°de téléphone Facsimile No. - N° de télécopieur	
Name and title of person authorized to sign on behalf of Vendor/Firm (type or print) Nom et titre de la personne autorisée à signer au nom du fournisseur/ de l'entrepreneur (taper ou écrire en caractères d'imprimerie)	
Signature	Date

This is an extension of the original request which closed on May 19, 2020. If you responded to the original RFI, there is no requirement to resubmit.

REQUEST FOR INFORMATION (RFI) RE: Supply and Demand of Methotrimепrazine

The Government of Canada recognizes that Canadians who are ill with COVID-19 need access to safe and effective medicines and treatments. As such, the Government of Canada is actively monitoring the impact of the COVID-19 pandemic on the supply of drugs in Canada.

Through this Request for Information (RFI), Canada is seeking to collect information from companies on availability of **methotrimепrazine tablets and injectable formulations**. This information will be used to inform the Government's response to the ongoing pandemic.

The priority of the Government of Canada is to ensure that there remains a stable supply of methotrimепrazine for patients who require it for treatments as currently approved by Health Canada. Health Canada is working with manufacturers to assess existing monthly demands to determine projected supply requirements.

This request is a tool to identify additional supply that has not already been earmarked to meet Canada's current needs for methotrimепrazine. The Government of Canada is interested in procuring up to a twelve-month supply, which would support existing efforts to ensure Canadians have access to the drugs they need. In light of ongoing fluctuations in global and domestic demand, should the Government proceed, an incremental procurement approach would be considered.

Please Note:

- If your company is currently working with the Government of Canada to address an existing shortage, we are not looking for information on products already identified to mitigate the shortage.
- The Government of Canada is also interested in receiving information about acceptable substitute drugs.

If your company is not currently working with the Government of Canada to address an existing shortage, or if you are working with Health Canada but may have access to additional product, we would welcome information on available methotrimепrazine or equivalent product. We are looking to ensure this drug is available for Canadians without affecting the supply currently available for the Canadian market through existing distribution channels.

The Government of Canada is aware that there are risks of drug shortages globally due to the pandemic and that the current drug shortages faced by Canada are not unique. As such, many jurisdictions are seeking to access the supply from many of the same sources. The Government

of Canada remains committed to working with its international partners on the issue of drug shortages to stabilize global supply chains as quickly as possible.

Supply Questions – ONLY additional supply (Not needed to meet current demand or proposed to mitigate a current shortage)	Tablet (oral)	Solution for Injection	Other Dosage Form (please provide specifications)
1. Specify the <u>unit strength</u> , <u>vial size</u> , and <u>pack size</u> (e.g. 2mg tablets, bottles of 100)			
2. The additional quantity available by June 30, 2020.			
3. The additional monthly quantity available July 1, 2020 and beyond.			
4. Estimated unit price (per XXX) of finished product, including to deliver to final destination.			
5. Are you currently supplying this			

product to the Canadian market? If yes, answer a-d below. If no, answer 6a-f below.			
a. Confirm that the quantities identified are in excess to supply that has already been earmarked.			
b. Do you have capacity to increase production of the product (Yes/No) If yes, please specify possible quantity/month and anticipated lead time for availability of product once a contract is finalized. Specify conditions, if any.			
c. Provide details of the market authorization (i.e. DIN(s))			

d. Provide the Drug Establishment License number of the Canadian manufacturer or importer, as the case may be.			
6. If product is not authorized for sale in Canada, a. do you currently have a submission with Health Canada? If Yes, please specify the type of authorization being sought (e.g. NOC, exceptional importation and sale) and include a submission number, if applicable. b. provide a list of countries in which the product is			

authorized for sale, if applicable				
c. Is the product fabricated outside of Canada? If yes, has a Canadian importer been identified? Provide the Drug Establishment License number of the importer, if applicable.				
d. Provide information about the product fabrication building(s) (Country name, Company name, Building address, Drug Establishment License number, if applicable)				

e. Provide information about the product Packing/ Labelling Building(s) (Country name, Company name, Building address)			
f. Provide information about the product Testing Building(s) (Country name, Company name, Building address)			

Vendor Managed Inventory Questions	Tablet	Solution for Injection	Other Dosage Form (please provide specifications)
1. The total quantity available that could be vendor held and managed (in Canada) on behalf of the Government of Canada for up to 24 months (inventory must be rotated out to ensure a minimum of 14 months of			

remaining shelf life).			
2. Storage location			
3. Estimated monthly cost for vendor held and managed inventory (flat rate or per (e.g., units, package, pallet, etc. – please specify) of finished product (if applicable).			
4. Expected hours of operation for shipment requests are Monday to Friday during normal business hours.			
5. Expected turnaround time for shipment requests (from time request is received to the shipment leaving the depot) is one business day.			
6. Minimum order size when shipping out of vendor held inventory (if applicable)			

API Questions (if conditional to availability)	Tablet	Solution for Injection	Other Dosage Form (please provide specifications)
1. The quantity of API available immediately (i.e. within 7 days) both in metric tons and the approximate number of finished units that could be produced.			
2. How many units are			

produced per metric tonne of bulk API?			
3. What is the shelf life of bulk API?			
4. What is the production time required to deliver finished products from the date of request to produce from bulk API?			
5. The additional quantity of API available monthly, July 1, 2020 and beyond			
6. Estimated price of API per metric tonne			
7. Estimated additional cost per unit to manufacture from bulk API to finished product, including delivery to final destination			
8. Estimated monthly cost for vendor held and managed inventory (per metric tonne) of API (if applicable)			
9. API Fabrication Building (Country name, Company name, Building address, DEL Number if available)			
10. API Product Packing/Labelling Building (Country name, Company name, Building address, DEL Number if available)			
11. API Product Testing Building (Country name, Company			

name, Building address, DEL Number if available)			
---	--	--	--

Please specify any caveats of conditions that would apply to the questions provided above. Additionally, for the inventories (units and API) described above, identify what quantities are currently held domestically and what is contingent on being imported into Canada.

Note: This is not a bid solicitation. Potential suppliers of any goods or services described in this RFI should not reserve stock or facilities, nor allocate resources, as a result of any information contained in this RFI. Also, the procurement of any goods and services described in this RFI will not necessarily follow this RFI. This RFI is simply indented to solicit feedback from industry with respect to the matters described in this RFI.

Canada will not reimburse any respondent for expenses incurred in responding to this RFI.

You are requested to submit a response by **June 4, 2020** by email at Eric.Vettoretti@tpsgc-pwgsc.gc.ca.